KYPROLIS (carfilzomib) for Injection is used for the treatment of patients with multiple myeloma

KYPROLIS is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.

KYPROLIS (carfilzomib) for Injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of KYPROLIS (carfilzomib) for Injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the KYPROLIS (carfilzomib) for Injection medicine cost price in India.

The order for KYPROLIS (carfilzomib) for Injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy.

KYPROLIS™ (carfilzomib) for Injection, for intravenous use Initial U.S. Approval: 2012

Generic Name: carfilzomib

For injection: 0.9 mg lyophilized powder in a single-dose vial for reconstitution and further dilution.

KYPROLIS (carfilzomib) for Injection

KYPROLIS (carfilzomib) for Injection is available.

Get In Touch

KYPROLIS (carfilzomib) for Injection suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand KYPROLIS (carfilzomib) for Injection on prescription and Import License in Patient's Name only.

For overseas patients, KYPROLIS (carfilzomib) for Injection can be made available in Send your enquiry to find KYPROLIS (carfilzomib) for Injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for KYPROLIS (carfilzomib) for Injection.

For KYPROLIS (carfilzomib) for Injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Three-Drug Combination Improves Progression-Free Survival in Patients with Multiple Myeloma For More Details

Kyprolis (Carfilzomib) For More Details

Channel Partner In India


  • Address:60/4, T&T House. Yusuf Sarai, New Delhi:110016
  • Phone +91-11-26532129
  • Email: IPN, New Delhi


  • Address: #308, Raheja Chambers, 12, Museum Road, Bangalore 560 001
  • Email: IPN, Bangalore


  • Address: 1/A R.G Kar Road, Shayambazar, Kolkata 700004
  • Email: IPN, Kolkata


  • Address: 203-A, 2nd Floor, Tower -11, Felix Square, IBB-2, Sushant Golf city, Lucknow 226030
  • Email: IPN, Lucknow